No Data
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
TD Cowen analyst Stacy Ku maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 23.8% and
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $41
Piper Sandler analyst David Amsellem maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate o
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Stifel analyst Annabel Samimy maintains $Supernus Pharmaceuticals(SUPN.US)$ with a hold rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.5
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study
Supernus Pharmaceuticals (SUPN) said data from an interim analysis of a phase 2a study of SPN-817 demonstrated "strong evidence" of clinical utility in epilepsy. The study is examining the safety and